Media Summary: Elizabeth Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, gives an overview of Michael Atkins, MD, of Georgetown University, Washington DC, outlines the Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, talks about the rationale and

Updated Results Of Axitinib And - Detailed Analysis & Overview

Elizabeth Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, gives an overview of Michael Atkins, MD, of Georgetown University, Washington DC, outlines the Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, talks about the rationale and Camillo Porta, MD, University of Bari Aldo Moro, Bari, Italy, comments on the final analysis of the JAVELIN Renal 101 trial ... Brian Rini, MD, from the Cleveland Clinic Taussig Cancer Institute on the Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at ...

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University ... Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, discusses the Anand Sharma, MD, DPhil, MBBS, MRCP, Mount Vernon Cancer Centre, Northwood, UK, provides an overview of In this video, Matthew Milowsky, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, shares insights on ... Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, explains how this is an exciting time for kidney cancer, ... Dr Motzer speaks with ecancer at ESMO 2018 in Munich about

Ulka N. Vaishampayan, MBBS, FAB, discusses the benefit of

Photo Gallery

Updated results of axitinib and nivolumab in previously treated mRCC
Promising results for axitinib and pembrolizumab in advanced renal cell cancer
KEYNOTE-426 rationale and results: pembro plus axitinib vs. sunitinib in mRCC
Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trial
Dr. Rini on the Results From His Axitinib and Sorafenib Trial
Dr. Rini Describes Axitinib's and Sorafenib's Side Effects
Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma
Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCC
Real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma
Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCC
Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo
Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma
View Detailed Profile
Updated results of axitinib and nivolumab in previously treated mRCC

Updated results of axitinib and nivolumab in previously treated mRCC

Elizabeth Plimack, MD, MS, Fox Chase Cancer Centre, Philadelphia, PA, gives an overview of

Promising results for axitinib and pembrolizumab in advanced renal cell cancer

Promising results for axitinib and pembrolizumab in advanced renal cell cancer

Michael Atkins, MD, of Georgetown University, Washington DC, outlines the

KEYNOTE-426 rationale and results: pembro plus axitinib vs. sunitinib in mRCC

KEYNOTE-426 rationale and results: pembro plus axitinib vs. sunitinib in mRCC

Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, talks about the rationale and

Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trial

Final results of avelumab and axitinib in RCC in the JAVELIN Renal 101 trial

Camillo Porta, MD, University of Bari Aldo Moro, Bari, Italy, comments on the final analysis of the JAVELIN Renal 101 trial ...

Dr. Rini on the Results From His Axitinib and Sorafenib Trial

Dr. Rini on the Results From His Axitinib and Sorafenib Trial

Brian Rini, MD, from the Cleveland Clinic Taussig Cancer Institute on the

Dr. Rini Describes Axitinib's and Sorafenib's Side Effects

Dr. Rini Describes Axitinib's and Sorafenib's Side Effects

Lead investigator Brian I. Rini, MD, a staff member in the Department of Solid Tumor Oncology at the Taussig Cancer Institute at ...

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

Dr. Rini on Axitinib for Treatment of Metastatic Renal Cell Carcinoma

Brian Rini, MD, associate professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University ...

Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCC

Updated analysis of KEYNOTE-426: pembro plus axitinib vs sunitinib in mRCC

Elizabeth Plimack, MD, MS, Fox Chase Cancer Center, Philadelphia, PA, discusses the

Real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma

Real-world efficacy of avelumab and axitinib in advanced renal cell carcinoma

Anand Sharma, MD, DPhil, MBBS, MRCP, Mount Vernon Cancer Centre, Northwood, UK, provides an overview of

Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCC

Pembrolizumab/Axitinib and Avelumab/Axitinib combo for RCC

In this video, Matthew Milowsky, MD, of the UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC, shares insights on ...

Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo

Kidney cancer updates: avelumab/axitinib, pembro/axitinib, bevacizumab/atezo & ipilimumab/nivo

Thomas Powles, MBBS, MRCP, MD, of Barts Cancer Institute, London, UK, explains how this is an exciting time for kidney cancer, ...

Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma

Avelumab and axitinib vs sunitinib in treating advanced renal cell carcinoma

Dr Motzer speaks with ecancer at ESMO 2018 in Munich about

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC

Dr. Vaishampayan on Axitinib Plus Pembrolizumab in Advanced RCC

Ulka N. Vaishampayan, MBBS, FAB, discusses the benefit of